Recent Updates

Modified on: 
Nov 26, 2020

The BloodTechNet program was launched in 2011 to facilitate the development of innovative educational resources that support the transfusion, cellular therapy and transplantation communities in Canada. The program is led by Canadian Blood Services’ Centre for Innovation with financial support from Grifols. For information about the next BloodTechNet program competition, visit blood.ca.

Transfusion
Organs and Tissues
Stem Cells
Modified on: 
Nov 26, 2020

Author: Rachel Ward, JD, BCom
Online publication date: August 2019
Target audience: health-care professionals and academics conducting research projects involving human participants.

This article provides health-care professionals and researchers with an overview of the frameworks that help protect individuals’ privacy in the context of research, a topic that is particularly relevant in a time of big data, artificial intelligence and significant advances in technologies that are reliant on data inputs.

Transfusion
Modified on: 
Nov 19, 2020

Authors: Youness Elkhalidy, MD, and Gwen Clarke, MD, FRCPC
Publication date: October 2020
Primary target audiences: Medical laboratory technologists (MLT) in a hospital laboratory, transfusion medicine physicians

The purpose of this document is to clarify the relevance of ABO subgroups for hospital blood banks selecting a red blood cell unit for transfusion and importance of working with Canadian Blood Services to investigate potential donors with an ABO subgroup.

Transfusion
Modified on: 
Nov 16, 2020

Platelets are the smallest of the blood cells, with a diameter of two to three microns and no nucleus. Their main function is to mediate primary hemostasis, though they are involved in a number of other processes including primary immunity, tumour progression and inflammation. 

Transfusion
Modified on: 
Nov 16, 2020

Immune globulin (Ig) products are generated from plasma collected from a large number of carefully screened donors. Ig products may be used as replacement therapy for immunodeficiency patients or as immunomodulatory therapy for autoimmune and alloimmune disorders. Ig products include intravenous Ig (IVIg), subcutaneous Ig (SCIg), RhD Ig (RhIg) and hyperimmune globulins.

Transfusion
Modified on: 
Nov 16, 2020

Abnormal bleeding may result from defects in platelets, coagulation factors and/or blood vessels. Screening tests for coagulation factor abnormalities include the activated Partial Thromboplastin Time (aPTT) and Prothrombin Time (PT) / International Normalized Ratio (INR). Thrombocytopenia is the most common platelet defect. Qualitative platelet defects may also occur and, in some cases, may be associated with thrombocytopenia. In patients with platelet defects, bleeding time and/or closure times using the platelet function analyzer (PFA-100/200TM) may be prolonged. Vascular defects may be accompanied by joint hyperflexibility or skin laxity. Effective treatment of hemostatic disorders requires accurate diagnosis and special coagulation testing that may include coagulation factor assays, inhibitor assays, and platelet function tests. An algorithmic approach to diagnosis is beyond the scope of this review.

Transfusion
Modified on: 
Nov 16, 2020

Apheresis involves the removal of whole blood from an individual and its separation into components. A specified component is retained and the remainder is returned to the individual. Therapeutic apheresis is used to treat patients with a variety of disorders and has become a relatively common treatment modality. The rationale and techniques for therapeutic apheresis, as well as the care of the apheresis patient, will be discussed in this chapter.

Transfusion
Modified on: 
Nov 16, 2020

While the practice of transfusion of blood products to neonatal and pediatric recipients has much in common with the transfusion of blood products to adults, there are several important differences and special circumstances. This chapter highlights the most common considerations that are unique to this group of patients.

Transfusion
Modified on: 
Nov 16, 2020

This chapter reviews the testing and treatments that are relevant for mothers and their fetuses/infants during pregnancy and postnatally to reduce the risks of hemolytic disease of the fetus and newborn (HDFN) and of immune thrombocytopenias.

Transfusion
Modified on: 
Nov 16, 2020

The approach to transfusion in emergent situations varies dramatically depending on the clinical scenario. The primary guiding determinant is the clinician’s assessment of the rapidity of bleeding, the severity of hemorrhage or amount of blood lost, and the clinical stability of the patient. Using the severely injured trauma patient as a case study, this chapter will discuss the principles of massive hemorrhage and resuscitation, with the inclusion of special situations such as obstetrical hemorrhage, where data are available.

Transfusion

Pages